InsiderTrades.com logo
Seshu Tyagarajan net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Seshu Tyagarajan Biography and Net Worth

CTO of Candel Therapeutics

Dr. Seshu Tyagarajan serves as Chief Technical and Development Officer at Candel Therapeutics. She brings over two decades of technical, manufacturing and development experience in biologics and cell and gene therapies (CGT). Before joining Candel, Dr. Tyagarajan served as Executive Director and Global Head, Late Stage CMC Strategy for CGT, at Novartis. As a member of the Novartis leadership team, she was responsible for building a CGT pipeline by integrating research, development and manufacturing, and for driving clinical and commercial manufacturing strategy for the CAR-T platform. She successfully led several BLAs/MAAs and INDs and was a key contributor to the groundbreaking BLA submission for Kymriah®, the first ever CAR-T therapy approved by the FDA.

Prior to Novartis, Dr. Tyagarajan held roles of increasing responsibility at Merck, Roche, Biogen Idec (now Biogen), and ImClone a subsidiary of Eli Lilly. Dr. Tyagarajan holds a Ph.D. in Chemical and Biochemical Engineering from Rutgers University and an M.S. in Bioengineering from Purdue University.

What is Seshu Tyagarajan's net worth?

The estimated net worth of Seshu Tyagarajan is at least $449.79 thousand as of March 17th, 2025. Dr. Tyagarajan owns 85,512 shares of Candel Therapeutics stock worth more than $449,793 as of December 5th. This net worth approximation does not reflect any other assets that Dr. Tyagarajan may own. Additionally, Dr. Tyagarajan receives a salary of $335,270.00 as CTO at Candel Therapeutics. Learn More about Seshu Tyagarajan's net worth.

How old is Seshu Tyagarajan?

Dr. Tyagarajan is currently 56 years old. There are 6 older executives and no younger executives at Candel Therapeutics. The oldest executive at Candel Therapeutics is Dr. Estuardo Aguilar-Cordova Inf., M.D., Ph.D., Founder & Director, who is 65 years old. Learn More on Seshu Tyagarajan's age.

What is Seshu Tyagarajan's salary?

As the CTO of Candel Therapeutics, Inc., Dr. Tyagarajan earns $335,270.00 per year. There are 2 executives that earn more than Dr. Tyagarajan. The highest earning executive at Candel Therapeutics is Dr. Paul-Peter Tak FMEDSCI, M.D., Ph.D., President, CEO & Director, who commands a salary of $1,120,000.00 per year. Learn More on Seshu Tyagarajan's salary.

How do I contact Seshu Tyagarajan?

The corporate mailing address for Dr. Tyagarajan and other Candel Therapeutics executives is , , . Candel Therapeutics can also be reached via phone at 617-916-5445 and via email at [email protected]. Learn More on Seshu Tyagarajan's contact information.

Has Seshu Tyagarajan been buying or selling shares of Candel Therapeutics?

Seshu Tyagarajan has not been actively trading shares of Candel Therapeutics over the course of the past ninety days. Most recently, Seshu Tyagarajan sold 31,278 shares of the business's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $8.82, for a transaction totalling $275,871.96. Following the completion of the sale, the chief technology officer now directly owns 85,512 shares of the company's stock, valued at $754,215.84. Learn More on Seshu Tyagarajan's trading history.

Who are Candel Therapeutics' active insiders?

Candel Therapeutics' insider roster includes Francesca Barone (Chief Scientific Officer), Paul Manning (Director), William Nichols (Chief Medical Officer), Charles Schoch (CFO), and Seshu Tyagarajan (CTO). Learn More on Candel Therapeutics' active insiders.

Are insiders buying or selling shares of Candel Therapeutics?

During the last twelve months, Candel Therapeutics insiders bought shares 1 times. They purchased a total of 1,250,000 shares worth more than $7,500,000.00. During the last twelve months, insiders at the sold shares 7 times. They sold a total of 79,525 shares worth more than $644,010.84. The most recent insider tranaction occured on July, 28th when insider William Garrett Nichols sold 937 shares worth more than $6,540.26. Insiders at Candel Therapeutics own 16.6% of the company. Learn More about insider trades at Candel Therapeutics.

Information on this page was last updated on 7/28/2025.

Seshu Tyagarajan Insider Trading History at Candel Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/17/2025Sell31,278$8.82$275,871.9685,512View SEC Filing Icon  
1/15/2025Sell14,322$7.22$103,404.8496,790View SEC Filing Icon  
11/29/2024Sell20,392$4.56$92,987.52125,657View SEC Filing Icon  
7/17/2024Sell14,851$6.47$96,085.97146,049View SEC Filing Icon  
7/11/2024Sell13,330$5.97$79,580.10160,900View SEC Filing Icon  
12/8/2022Buy3,000$1.69$5,070.003,000View SEC Filing Icon  
See Full Table

Seshu Tyagarajan Buying and Selling Activity at Candel Therapeutics

This chart shows Seshu Tyagarajan's buying and selling at Candel Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Candel Therapeutics Company Overview

Candel Therapeutics logo
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Read More

Today's Range

Now: $5.26
Low: $4.97
High: $5.32

50 Day Range

MA: $5.21
Low: $4.42
High: $6.55

2 Week Range

Now: $5.26
Low: $4.25
High: $14.60

Volume

1,381,428 shs

Average Volume

682,855 shs

Market Capitalization

$288.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A